What cancer biomarkers can ctc's detect that ctdna can't?30 May 2025 17:27
AI Overview
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are both liquid biopsy biomarkers for cancer, but they offer different insights. CTCs can detect tumor-specific surface markers, cellular morphology, and microenvironment interactions, which ctDNA alone cannot. Additionally, CTCs can assess tumor burden and identify high-risk patients for more intensive therapies.
Here's a more detailed breakdown:
Surface Markers:
CTCs allow for the identification of tumor-specific surface markers like ***HER2***, estrogen receptor, and prostate-specific membrane ***antigen***, which can be helpful in understanding tumor heterogeneity and predicting treatment response.
Morphology and Microenvironment:
CTCs can reveal information about the cellular morphology and interactions within the tumor microenvironment, which is crucial for understanding drug resistance and treatment planning.
Tumor Burden:
CTC quantification can provide insights into the overall tumor burden, particularly in aggressive cancers, and help predict treatment response.
High-Risk Patient Identification:
CTCs can help identify high-risk patients, such as those with a higher number of CTCs, who may benefit from more intensive therapies like adjuvant chemotherapy.
In contrast, ctDNA primarily provides genetic information:
Genetic Mutations:
ctDNA can detect mutations, including insertions, deletions, and single nucleotide variants, which can guide targeted therapies.
Copy Number Variations:
ctDNA can detect copy number variations and genome-wide rearrangements, providing information about the overall genomic landscape of the tumor.
DNA Methylation:
ctDNA can also be used to assess DNA methylation patterns, which can be altered in cancer and are potential biomarkers for early cancer detection.
Key Differences and Complementary Roles:
Complementary Information:
Both CTCs and ctDNA provide valuable information, and they can be used in combination to gain a more comprehensive understanding of the tumor.
Drug Resistance:
CTCs can provide insights into the phenotypic characteristics of tumors, including drug resistance mechanisms, which ctDNA alone may not fully capture.
Treatment Planning:
By integrating information from both CTCs and ctDNA, clinicians can make more informed decisions about drug selection and treatment planning, potentially improving patient outcomes.
===================================
Both CtDna and CTC information is needed. The NHS should have Parsortix machines in their labs in my opinion, alongside the CtDna capture/analysis equipment.
All IMHO.
Sign In
Follow the stocks
